Download Free Sample Report

Human Rabies Vaccines Market, Global Outlook and Forecast 2023-2029

Human Rabies Vaccines Market, Global Outlook and Forecast 2023-2029

  • Published on : 10 June 2023
  • Pages :79
  • Report Code:SMR-7710820

Download Report PDF Instantly

Leave This Empty:

Secure

Report overview

Rabies Vaccine is an immunization drug used to prevent rabies in people who have been bitten by an animal or otherwise exposed to the rabies virus.
There are a number of rabies vaccines available that are both safe and effective. They can be used to prevent rabies, before or after exposure to the rabies virus, which is commonly caused by a dog bite or a bat bite.
This report aims to provide a comprehensive presentation of the global market for Human Rabies Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Rabies Vaccines. This report contains market size and forecasts of Human Rabies Vaccines in global, including the following market information:
Global Human Rabies Vaccines Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Human Rabies Vaccines Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Human Rabies Vaccines companies in 2022 (%)
The global Human Rabies Vaccines market was valued at US$ 1086.6 million in 2022 and is projected to reach US$ 1370.3 million by 2029, at a CAGR of 3.4% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global Human Rabies Vaccine market leaders include Chengda Bio, Bharat Biotech, Bavarian Nordic, Sanofi-Pasteur, etc. All of the above hold over 65 percent market share.
Asia-Pacific is the largest consumption area, with a consumption market share close to 60%. Besides, North Americas is the second largest consumption area with a consumption market share of over 15%.
The classification of Human Rabies Vaccine includes Vero Cell, BHK, Chick Embryo Cell, Human Diploid Cells, and Others. In addition, the proportion of Vero Cell rabies vaccines is about 85%.
Human Rabies Vaccine is widely used for Pre-exposure and Post-exposure. The segment of Human Rabies Vaccine used for Post-exposure and the market share is over 70% of the share.
We surveyed the Human Rabies Vaccines manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Human Rabies Vaccines Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Human Rabies Vaccines Market Segment Percentages, by Type, 2022 (%)
Vero Cell Rabies Vaccine
BHK
Chick Embryo Cell Rabies Vaccine
Others
Global Human Rabies Vaccines Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Human Rabies Vaccines Market Segment Percentages, by Application, 2022 (%)
Pre-Exposure Prophylaxis
Post-Exposure Prophylaxis
Global Human Rabies Vaccines Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Human Rabies Vaccines Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Human Rabies Vaccines revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Human Rabies Vaccines revenues share in global market, 2022 (%)
Key companies Human Rabies Vaccines sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Human Rabies Vaccines sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi Pasteur?Inc.
Novartis Vaccines and Diagnostics Ltd.
Cadila Pharmaceuticals Ltd.
GlaxoSmithKline Biologicals
Merck?Co Inc.
Wyeth pharmaceuticals
Berna Biotech Ltd.
Medimmune LLC
Outline of Major Chapters:
Chapter 1: Introduces the definition of Human Rabies Vaccines, market overview.
Chapter 2: Global Human Rabies Vaccines market size in revenue and volume.
Chapter 3: Detailed analysis of Human Rabies Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Human Rabies Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Human Rabies Vaccines capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.